Abstract

D-norpseudoephedrine (NPE), also known as cathine, is found naturally in the shrub Catha edulis “Khat.” NPE has been widely used as an appetite suppressant for the treatment of obesity. Although it is known that NPE acts on α1-adrenergic receptors, there is little information about the role of dopamine receptors on NPE’s induced anorectic and weight loss effects. Equally untouched is the question of how NPE modulates neuronal activity in the nucleus accumbens shell (NAcSh), a brain reward center, and a pharmacological target for many appetite suppressants. To do this, in rats, we characterized the pharmacological effects induced by NPE on weight loss, food intake, and locomotion. We also determined the involvement of dopamine D1- and D2-like receptors using systemic and intra-NAcSh antagonists, and finally, we recorded single-unit activity in the NAcSh in freely moving rats. We found that NPE decreased 24-h food intake, induced weight loss, and as side effects increased locomotor activity and wakefulness. Also, intraperitoneal and intra-NAcSh administration of D1 and D2 dopamine antagonists partially reversed NPE’s induced weight loss and food intake suppression. Furthermore, the D1 antagonist, SCH-23390, eliminated NPE-induced locomotion, whereas the D2 antagonist, raclopride, only delayed its onset. We also found that NPE evoked a net activation imbalance in NAcSh that propelled the population activity trajectories into a dynamic pharmacological brain state, which correlated with the onset of NPE-induced wakefulness. Together, our data demonstrate that NPE modulates NAcSh spiking activity and that both dopamine D1 and D2 receptors are necessary for NPE’s induced food intake suppression and weight loss.

Highlights

  • Obesity is currently a pandemic affecting more than 650 million people worldwide

  • Obesity is primarily treated with exercise and diet, appetite suppressants can aid in weight loss (Wing and Hill, 2001; Joo and Lee, 2014; Brett, 2019)

  • We found that mild stimulants, including diethylpropion, phentermine, and bupropion, suppressed food intake, induced weight loss, and modulated neural activity in the nucleus accumbens shell (NAcSh) (Kalyanasundar et al, 2015; Perez et al, 2019), a brain region with robust dopaminergic innervation involved in feeding, sleep, and locomotor behavior (Kelley et al, 2005; Palmiter, 2007; Tellez et al, 2012)

Read more

Summary

Introduction

Obesity is currently a pandemic affecting more than 650 million people worldwide. obesity is primarily treated with exercise and diet, appetite suppressants can aid in weight loss (Wing and Hill, 2001; Joo and Lee, 2014; Brett, 2019). Subsequent appetite suppressants were mainly amphetamine congeners but with less intense properties (Zelger and Carlini, 1980; Kalix and Khan, 1984; Balint et al, 2009; Khan et al, 2012) These drugs exert their pharmacological effects by stimulating the release of norepinephrine, serotonin, and dopamine (DA) via uptake inhibition (Baumann et al, 2000; Drevets et al, 2001; Rothman et al, 2001; Broening et al, 2005).

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call